168P Sacituzumab govitecan (SG) efficacy in patients with metastatic triple-negative breast cancer (mTNBC) by HER2 immunohistochemistry (IHC) status: Findings from the phase III ASCENT study
Title:
168P Sacituzumab govitecan (SG) efficacy in patients with metastatic triple-negative breast cancer (mTNBC) by HER2 immunohistochemistry (IHC) status: Findings from the phase III ASCENT study
Author:
Hurvitz, S.A. Bardia, A. Punie, K. Kalinsky, K. Cortés, J. O'Shaughnessy, J. Carey, L.A. Rugo, H.S. Yoon, O.K. Pan, Y. Delaney, R.J. Hofsess, S. Hodgkins, P. Phan, S-C. Dieras, V.